Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag and FcγRIIIA Polymorphism in Refractory ITP
NCT02877212Phase 3Unknown
- Sponsor
- National Institute of Blood and Marrow Transplant
- Start
- Jul 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of eltrombopag in immune thrombocytopenic purpura (ITP), sponsored by National Institute of Blood and Marrow Transplant. Status: unknown.
02
Drugs
eltrombopag
03
Conditions
immune thrombocytopenic purpura (ITP)
Beyond the preview
Go deeper on NCT02877212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02877212.